Coverart for item
The Resource Clinically Relevant Mycoses : A Practical Approach, Elisabeth Presterl, editor, (electronic book)

Clinically Relevant Mycoses : A Practical Approach, Elisabeth Presterl, editor, (electronic book)

Label
Clinically Relevant Mycoses : A Practical Approach
Title
Clinically Relevant Mycoses
Title remainder
A Practical Approach
Statement of responsibility
Elisabeth Presterl, editor
Contributor
Subject
Language
eng
Cataloging source
EBLCP
Dewey number
571.9/95
Index
no index present
LC call number
RC117
Literary form
non fiction
Nature of contents
dictionaries
http://library.link/vocab/relatedWorkOrContributorName
Presterl, Elisabeth
http://library.link/vocab/subjectName
Mycoses
Label
Clinically Relevant Mycoses : A Practical Approach, Elisabeth Presterl, editor, (electronic book)
Instantiates
Publication
Note
  • Description based upon print version of record
  • 5.2.1 Case Presentation
Antecedent source
file reproduced from an electronic resource
Contents
  • 1.2.4 Aspergillus-Specific Lateral Flow Device Test (LFD)1.3 1-3-[beta]-d-Glucan (BDG) as a Marker for Invasive Fungal Infection; 1.4 Antifungal Susceptibility Testing (AST); References; 2: Immune System and Pathogenesis; 2.1 Introduction; 2.2 Pathogenesis; 2.3 Host Immune System Response to Fungal Infection; 2.3.1 Innate Immune System Response to Fungal Infection; 2.3.2 Innate Immune Cells and the Link with Adaptive Response; 2.4 Link Between Immunopathogenesis and Clinical Risk Factors for Most Common Invasive Fungal Infections; References; 3: Antifungal Agents; 3.1 Introduction
  • Intro; Preface; Introduction; Objective of This Book; Acknowledgments; Contents; Part I: General; 1: What Is the Target? Clinical Mycology and Diagnostics; 1.1 Epidemiology; 1.1.1 Yeasts; 1.1.2 Filamentous Fungi; 1.1.2.1 Relevant Diagnostic Material for Diagnosis of Clinical Mycoses; 1.1.2.2 Currently Available Diagnostic Methods; 1.1.2.3 Histopathology; 1.1.2.4 Microscopy; 1.1.2.5 Culture; 1.1.2.6 Surrogate Markers: Biomarkers of Invasive Fungal Infections; 1.2 Antigen and Antibody Detection; 1.2.1 Candidiasis; 1.2.2 Cryptococcosis; 1.2.3 Invasive Aspergillosis (IA)
  • 3.2 Polyenes (Amphotericin B)3.2.1 Lipid-Associated Formulations of AMB; 3.3 5-Fluorocytosine; 3.4 Azole Antifungal Agents; 3.4.1 Fluconazole; 3.4.2 Voriconazole; 3.4.3 Itraconazole; 3.4.4 Posaconazole; 3.4.5 Isavuconazole; 3.5 Echinocandins; 3.5.1 Caspofungin; 3.5.2 Micafungin; 3.5.3 Anidulafungin; 3.6 Allylamines; References; Part II: Clinical Disease; 4: Clinical Syndromes: Candida and Candidosis; 4.1 Introduction; 4.2 Pathogens; 4.3 Epidemiology; 4.3.1 Superficial Candidosis; 4.3.2 Systemic Candidosis and Candidaemia; 4.4 Clinical Presentation
  • 4.4.1 Superficial Candidosis4.4.1.1 Oral Candidosis (OPC); 4.4.1.2 Vulvovaginal Candidosis (VVC); 4.4.1.3 Oesophageal Candidosis (EC); 4.4.1.4 Chronic Muco-cutaneous Candidosis (CMC); 4.4.2 Systemic Candidosis and Candidaemia; 4.4.2.1 Terminology; 4.4.2.2 Prognostic Factors and Scores; 4.4.2.3 Candidaemia; Catheter-associated Candidaemia; 4.4.2.4 Arthritis/Osteomyelitis/Spondylodiscitis; 4.4.2.5 Candiduria and Urinary Tract Infections; 4.4.2.6 Chorioretinitis and Endophthalmitis; 4.4.2.7 Endocarditis; 4.4.2.8 Hepato-splenic Candidosis (Chronic Disseminated Candidosis)
  • 4.4.2.9 Intra-abdominal Candidosis4.4.2.10 Meningitis/Meningoencephalitis; 4.4.2.11 Pulmonary Candidosis and Mediastinitis; 4.5 Diagnosis; 4.6 Treatment; 4.6.1 Systemic Candidosis; 4.6.1.1 Prophylaxis; 4.6.1.2 Empiric/Pre-emptive Antifungal Therapy; 4.6.1.3 Therapy for Proven Systemic IFD (Non-granulocytopenic Patient); 4.6.1.4 Catheter Management; 4.7 Infection Control; 4.8 Antifungal Stewardship; References; 5: Clinical Syndromes: Aspergillus; 5.1 Diagnosis; 5.1.1 Clinical Presentations of IAI; 5.1.2 Clinical Presentation; 5.2 Superficial Aspergillus Infection
Dimensions
unknown
Extent
1 online resource (224 p.)
File format
one file format
Form of item
online
Isbn
9783319923000
Level of compression
unknown
Quality assurance targets
unknown
Reformatting quality
unknown
Specific material designation
remote
System control number
  • on1080432472
  • (OCoLC)1080432472
Label
Clinically Relevant Mycoses : A Practical Approach, Elisabeth Presterl, editor, (electronic book)
Publication
Note
  • Description based upon print version of record
  • 5.2.1 Case Presentation
Antecedent source
file reproduced from an electronic resource
Contents
  • 1.2.4 Aspergillus-Specific Lateral Flow Device Test (LFD)1.3 1-3-[beta]-d-Glucan (BDG) as a Marker for Invasive Fungal Infection; 1.4 Antifungal Susceptibility Testing (AST); References; 2: Immune System and Pathogenesis; 2.1 Introduction; 2.2 Pathogenesis; 2.3 Host Immune System Response to Fungal Infection; 2.3.1 Innate Immune System Response to Fungal Infection; 2.3.2 Innate Immune Cells and the Link with Adaptive Response; 2.4 Link Between Immunopathogenesis and Clinical Risk Factors for Most Common Invasive Fungal Infections; References; 3: Antifungal Agents; 3.1 Introduction
  • Intro; Preface; Introduction; Objective of This Book; Acknowledgments; Contents; Part I: General; 1: What Is the Target? Clinical Mycology and Diagnostics; 1.1 Epidemiology; 1.1.1 Yeasts; 1.1.2 Filamentous Fungi; 1.1.2.1 Relevant Diagnostic Material for Diagnosis of Clinical Mycoses; 1.1.2.2 Currently Available Diagnostic Methods; 1.1.2.3 Histopathology; 1.1.2.4 Microscopy; 1.1.2.5 Culture; 1.1.2.6 Surrogate Markers: Biomarkers of Invasive Fungal Infections; 1.2 Antigen and Antibody Detection; 1.2.1 Candidiasis; 1.2.2 Cryptococcosis; 1.2.3 Invasive Aspergillosis (IA)
  • 3.2 Polyenes (Amphotericin B)3.2.1 Lipid-Associated Formulations of AMB; 3.3 5-Fluorocytosine; 3.4 Azole Antifungal Agents; 3.4.1 Fluconazole; 3.4.2 Voriconazole; 3.4.3 Itraconazole; 3.4.4 Posaconazole; 3.4.5 Isavuconazole; 3.5 Echinocandins; 3.5.1 Caspofungin; 3.5.2 Micafungin; 3.5.3 Anidulafungin; 3.6 Allylamines; References; Part II: Clinical Disease; 4: Clinical Syndromes: Candida and Candidosis; 4.1 Introduction; 4.2 Pathogens; 4.3 Epidemiology; 4.3.1 Superficial Candidosis; 4.3.2 Systemic Candidosis and Candidaemia; 4.4 Clinical Presentation
  • 4.4.1 Superficial Candidosis4.4.1.1 Oral Candidosis (OPC); 4.4.1.2 Vulvovaginal Candidosis (VVC); 4.4.1.3 Oesophageal Candidosis (EC); 4.4.1.4 Chronic Muco-cutaneous Candidosis (CMC); 4.4.2 Systemic Candidosis and Candidaemia; 4.4.2.1 Terminology; 4.4.2.2 Prognostic Factors and Scores; 4.4.2.3 Candidaemia; Catheter-associated Candidaemia; 4.4.2.4 Arthritis/Osteomyelitis/Spondylodiscitis; 4.4.2.5 Candiduria and Urinary Tract Infections; 4.4.2.6 Chorioretinitis and Endophthalmitis; 4.4.2.7 Endocarditis; 4.4.2.8 Hepato-splenic Candidosis (Chronic Disseminated Candidosis)
  • 4.4.2.9 Intra-abdominal Candidosis4.4.2.10 Meningitis/Meningoencephalitis; 4.4.2.11 Pulmonary Candidosis and Mediastinitis; 4.5 Diagnosis; 4.6 Treatment; 4.6.1 Systemic Candidosis; 4.6.1.1 Prophylaxis; 4.6.1.2 Empiric/Pre-emptive Antifungal Therapy; 4.6.1.3 Therapy for Proven Systemic IFD (Non-granulocytopenic Patient); 4.6.1.4 Catheter Management; 4.7 Infection Control; 4.8 Antifungal Stewardship; References; 5: Clinical Syndromes: Aspergillus; 5.1 Diagnosis; 5.1.1 Clinical Presentations of IAI; 5.1.2 Clinical Presentation; 5.2 Superficial Aspergillus Infection
Dimensions
unknown
Extent
1 online resource (224 p.)
File format
one file format
Form of item
online
Isbn
9783319923000
Level of compression
unknown
Quality assurance targets
unknown
Reformatting quality
unknown
Specific material designation
remote
System control number
  • on1080432472
  • (OCoLC)1080432472

Library Locations